Barclays Raises Relay Therapeutics Price Target to $21

Analysts see potential 46% upside for the biotech stock

Apr. 8, 2026 at 4:55pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic financial machinery and equipment, conveying a sense of the complex technological infrastructure underlying the modern banking system.Barclays' increased price target for Relay Therapeutics highlights Wall Street's optimism around the biotech's computational drug discovery platform.Cambridge Today

Investment bank Barclays has increased its price target for Relay Therapeutics (NASDAQ:RLAY) from $17 to $21, representing a potential upside of 46.57% from the stock's current trading price. Barclays maintained its 'Overweight' rating on the biotech company, citing positive momentum in Relay's drug development pipeline.

Why it matters

Relay Therapeutics is a clinical-stage biotech focused on developing precision therapies for cancer. The increased price target from a major investment bank signals growing confidence in the company's ability to advance its drug candidates through the development and regulatory process, which could translate to significant gains for investors if the pipeline continues to progress.

The details

In a research note, Barclays analysts cited Relay Therapeutics' recent progress, including positive data readouts and the advancement of its lead oncology programs. The firm believes Relay's proprietary drug discovery platform, which leverages computational modeling and structural biology, positions the company well to develop novel cancer treatments.

  • Barclays raised its price target on Relay Therapeutics on April 8, 2026.

The players

Relay Therapeutics

A clinical-stage biotechnology company focused on developing precision therapies for cancer using its proprietary drug discovery platform.

Barclays

A major global investment bank that provides financial services and research coverage for public companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The increased price target from Barclays underscores the growing optimism around Relay Therapeutics' potential to develop innovative cancer treatments using its unique computational drug discovery approach. As the company continues to advance its pipeline, investors will be closely watching for further progress and potential value creation.